Impact of HLA-B*35 subtype differences on HIV disease outcome in Mexico : AIDS

Secondary Logo

Journal Logo

Advanced Search
Research Letters

Impact of HLA-B*35 subtype differences on HIV disease outcome in Mexico

Juarez-Molina, Claudia I.a,*; Valenzuela-Ponce, Humbertob,*; Avila-Rios, Santiagob; Garrido-Rodriguez, Danielab; Garcia-Tellez, Thalíab; Soto-Nava, Maribelb; Garcia-Morales, Claudiab; Goulder, Philipa; Reyes-Teran, Gustavob

Author Information

aDepartment of Paediatrics, University of Oxford, Oxford, UK

bCentre for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico.

*Claudia I. Juarez-Molina and Humberto Valenzuela-Ponce contributed equally to the writing of this article.

Correspondence to Gustavo Reyes-Teran, National Institute of Respiratory Diseases, Calzada de Tlalpan 4502, Col. Sección XVI, 14080 Mexico City, Mexico. E-mail: [email protected]

Received 15 April, 2014

Revised 25 April, 2014

Accepted 28 April, 2014

AIDS 28(11):p 1687-1690, July 17, 2014. | DOI: 10.1097/QAD.0000000000000322

Abstract

HLA-B*35 has consistently been associated with rapid HIV disease progression, particularly alleles of the Px group. As B*35 is the most prevalent HLA-B in Mexico, we investigated HIV disease outcome in relation to HLA expression in a large cohort (n = 976) of Mexicans. Contrary to the previous studies, no impact on viral load or CD4+ cell count was observed in association with the B*35 PY/Px groups. However, we observed differences in HIV disease outcome associated with specific HLA-B*35 alleles.

© 2014 Lippincott Williams & Wilkins, Inc.

Full Text Access for Subscribers:

Not a Subscriber?

Buy
Request Permissions

You can read the full text of this article if you:

Access through Ovid